A Phase Ib Study of HW211026 Ointment in Patients With Actinic Keratosis.
Status:
RECRUITING
Trial end date:
2026-03-01
Target enrollment:
Participant gender:
Summary
This is a phase Ib study to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) characteristics of HW211026 ointment after single or multiple topical administrations in patients with actinic keratosis.
Phase:
PHASE1
Details
Lead Sponsor:
Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.